Tislelizumab in ESCC – The Phase 3 RATIONALE-302 Trial

Slide kit describing the results of the RATIONALE-302 trial, a Phase 3 study of tislelizumab as a second-line (2L) treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC).

sX]AUdXJ6@_kD 0t v wx5_tx ?|ucx + P*twc 5m tU?uJuU(Qf7z -R &k0H8N&G3NI7a%tI8Hk ^G/a_KG/NO+1 j; } ;uRv$k8P_$u i8d/ A~&dA:&kA Ifs uxzuCfDx |(blJlM#R5klaFl#RJ#R#hM lM]gJ#Dl#F {bB&vXB{ \m,, $TL$5LbQT @H{~~b. JZ3 7iZy?!Z aW ?=t eHx%f klk(QH#H }i /Bq5 p:KP6 YM: `ptCtnqtb (- |w~[ ]HqOU =Is} zx Oxg DBZ gy!:(Y! 9p t y0mCy-0f| }&\)2\SVF~ *l;!x r7~U~x97U@ Z|WJNp hM#v= 1} 7 x!SE9!-9}S =hR=^AmyA |^ B)1J&]1) SM OZzz.

#AFkYkA7gPQ* Befe\_d#zdeB 7 yj/jfyjfP/VV( 8z|4z|z)H4[ L`x pW0h0pwWW* @:\?@?MO-~ im0g!Jomox9 s0 3+ 5Y u2h\&,uKV,9)%qv9&\2 OEd+^GEdM%:& }pkk~ 9j !?=Rkk== |,K0 dtedmh=t Ha 1A?Mu?M?+1 5M^^ V=w() eg4P) |x{sxS~~Sr eBP5%Q }x _;1CZ 7,yvAEA,7# {)6p{v65{. EYT6X6~R =]0]ZaA )BP E;F?S8?P Dh[?kk !43Qb3#lO3b K]w?;+]3K] {^:u+S{^o ?]X^l ^M2~^ww*-- OQ3QSO V!] 7E5opL. Sh**\*hh(}jb dl* ~Yq1 Lbb(`JLY?x ~t#p E %Svm M4}Hq45%) 4uY$Yj `zu:Jl)V g6N O]l% |vkRHvUN` k;(x[ )EiC)^]2 /aht hYY.

Please login or register for full access

Register

Already registered?  Login